US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Faron at Proactive One2One Investor Forum

Faron Pharmaceuticals Ltd. ("Faron")   Faron to Present at the Proactive One2One Investor Forum   Press Release, January 24, 2022 at 02:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM (EET)   TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron, will participate in the Proactive One2One Investor

Faron to Present at the Virtual H.C. Wainwright Global Investor Conference

Faron Pharmaceuticals Ltd (“Faron”) Faron to Present at the Virtual H.C. Wainwright Global Investor Conference   TURKU, FINLAND / BOSTON, MA, September 7, 2021 – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announced that Dr. Juho Jalkanen, Chief Development Officer of Faron, will present at the virtual H.C. Wainwright Global Investor Conference. Dr. Jalkanen’s presentation will be

Notice of Full-Year Results and Annual Report

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Notice of Full-Year Results and Annual Report Company announcement, 25 February 2021 at 7.00 am GMT / 9.00 am EET TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company, will publish its audited full-year results for the twelve months ended 31 December 2020 on Thursday 25 March 2021 at 7:00 GMT / 9:00 EET. The Annual Report 2020, including audited financial statements for the full year, will be published on the same day. A virtual briefing and Q&A session for

Update on TRAUMAKINE development

Faron Pharmaceuticals Oy (“Faron” or the “Company”) · U.S. Food and Drug Administration (FDA) approval of new HIBISCUS study protocol in patients with COVID-19 infection · Company seeking patent protection for the sequential use of IV interferon beta-1a and corticosteroids · Pipeline expansion into additional organ protection indications · CMC scale-up in progress Company announcement, 26 January 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces

MATINS trial data presented at ESMO

Data from completed Part I of bexmarilimab MATINS trial presented at ESMO Virtual Congress 2020TURKU – FINLAND, 18 September 2020 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today announces details from an oral presentation being held at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, showcasing data from the Company’s ongoing MATINS trial to the scientific community. The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of bexmarilimab, Faron's wholly-owned novel

Change of Adviser

Faron Pharmaceuticals Oy (“Faron” or the “Company”)Company announcement, 27 July 2020 at 9.00 AM (EET) TURKU - FINLAND, 27 July 2020 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce that Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company with immediate effect.  Panmure Gordon (UK) Limited continues to act as the Company’s Broker. For further information, please contact: Faron Pharmaceuticals Oy Dr Markku Jalkanen, Chief Executive Officer investor.relations@faron.

Managers’ transactions

(“Faron” or the “Company”)Company announcement, 8 July 2020 at 5 PM (EEST) TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 4,400 ordinary shares in Faron at a price of €3.510 per share on 8 July 2020. Following these purchases, Mr Hänninen holds 54,697 ordinary shares in the Company. The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

MATINS Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”) ·Safety and efficacy results from Part I of MATINS study presented in poster at ASCO20 Virtual · Patient recruitment for Part II in multiple cohorts progressing well    Company announcement, 01 June 2020 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the safety and efficacy results from Part I of the MATINS trial have been presented in a poster at the virtual ASCO20 (American Society of

Faron announces R&D Day to be held in June

Faron Pharmaceuticals Oy (“Faron” or the “Company”)Company announcement, 28 May 2020 at 9.00 AM (EET)   TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT. The event will provide an opportunity for the Company’s management team to present its R&D strategy and provide insight into Faron’s two clinical stage programmes. Management will discuss the Company’s wholly-owned novel precision cancer

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe